In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

The Dow, S&P 500, and Nasdaq rose Thursday as the stock market digested data on retail sales and jobless claims.

Sarepta's stock is jumping Thursday morning after the company announced a restructuring plan. Thomas Fuller / SOPA Images / LightRocket via Getty Images ...

Sarepta Therapeutics SRPT -2.17% is restructuring, laying off 36% of its workforce and making changes to its executive team. The restructuring is expected to save $400 million a year, the gene ...

Sarepta Therapeutics stock (NASDAQ: SRPT) experienced a significant turnaround on Wednesday, with shares rising 33% in after-hours trading following the announcement of an extensive restructuring ...

In the latest quarter, 35 analysts provided ratings for Sarepta Therapeutics SRPT, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing ...

TSMC shares rose 4% in premarket trade as the contract chip manufacturer lifted its 2025 sales guidance. Sarepta Therapeutics stock jumped 34% as the company set plans to lay off more than a third ...

↗️ TSMC (TSM): The world's largest contract chip maker delivered a record profit last quarter and said it was speeding up its expansion in Arizona ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an investment analysis.

The country music legend doesn't often mix it up in politics but she is speaking out against one of Trump's initiatives.

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the deaths of two Duchenne muscular dystrophy (DMD) patients following ...